<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792400</url>
  </required_header>
  <id_info>
    <org_study_id>H-15018701</org_study_id>
    <nct_id>NCT02792400</nct_id>
  </id_info>
  <brief_title>The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors</brief_title>
  <official_title>The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In normal physiology, glucagon from pancreatic alpha cells plays an important role in
      maintaining glucose homeostasis via its regulatory effect on hepatic glucose production.
      Patients with type 2 diabetes exhibit elevated plasma glucagon levels in the fasting state,
      and in response to ingestion of glucose or a mixed meal.glucagon, glucagon concentrations
      fail to decrease appropriately and may even increase. This diabetic hyperglucagonaemia may
      therefore contribute importantly to the hyperglycaemia of the patients.

      Several glucose-lowering treatment modalities have been shown to affect glucagon levels in
      patients with type 2 diabetes, but the role of glucagon in the glucose-lowering effects of
      these treatment modalities has been difficult to discern. By using a glucagon receptor
      antagonist (GRA) the investigators will exploit glucagon receptor antagonism to delineate the
      role of glucagon during treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors and
      dipeptidyl peptidase 4 (DPP-4) inhibitors, which have been shown to increase and decrease
      plasma glucagon levels, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in postprandial glucose excursions (linagliptin)</measure>
    <time_frame>Area under the curve (AUC) time frame: 0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 105, 120, 150, 180, 210, 240 minutes. Comparison between experimental days with linagliptin (A1, A2, A3, A4)</time_frame>
    <description>Difference in postprandial glucose excursions (measured as incremental (baseline substracted) area under the curve (AUC) values).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in postprandial glucose excursions</measure>
    <time_frame>Area under the curve (AUC) time frame: 0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 105, 120, 150, 180, 210, 240 minutes. Comparison between experimental days with empagliflozin (B1, B2, B3, B4)</time_frame>
    <description>Difference in postprandial glucose excursions (measured as incremental (baseline substracted) area under the curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>Plasma concentration of 6,6^2 H2-glucose and U-13C^6-glucose at times: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes.</time_frame>
    <description>Glucose rate of appearance will be calculated by the non-steady state equation using double tracer technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipolysis</measure>
    <time_frame>Plasma concentration of 1,1,2,3,3-^2-H5 - glycerol measured at times: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes.</time_frame>
    <description>Glycerol disappearance will be calculated by the non-steady state equation using double tracer technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/plasma concentrations of insulin, C-peptide, glucagon, GIP and GLP-1.</measure>
    <time_frame>: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>VAS scales will be handed out at time 0, 30, 60, 90, 120, 150, 180 and 240 minutes.</time_frame>
    <description>Appetite will be evaluated with a visual analogue scale (VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy intake (kcal/kJ)</measure>
    <time_frame>At time 240 to 270, the participants will eat an ad libitum meal.</time_frame>
    <description>At the end of the standardised liquid meal test, food intake will be examined with an ad libitum meal. The weight of the food will be measured in grams and calculated to the energy intake in kcal/kJ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure (mmHg)</measure>
    <time_frame>Measured at time 0 and time 210 minutes.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pulse rate (beat per minute)</measure>
    <time_frame>Measured at time 0 and at time 210 minutes.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in gastric emptying</measure>
    <time_frame>-30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes</time_frame>
    <description>Measurement of p-paracetamol. Measurement of time to peak and incremental area under the curve (iAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acids</measure>
    <time_frame>-30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes</time_frame>
    <description>Serum values of free fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Fibroblast growth factor-21</measure>
    <time_frame>-30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>-60 to -50 and 35 to 45</time_frame>
    <description>Resting energy expenditure evaluated by 10 minutes of indirect calorimetry.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>A1: GRA-placebo + MEAL + DPP4-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LY2409021 placebo + 4 hour standardised liquid mixed-meal test + linagliptin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2: GRA-active + MEAL + DPP4-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + linagliptin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3: GRA-placebo + MEAL + DPP4-active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4: GRA-active + MEAL + DPP4-active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1: GRA-placebo + MEAL + SGLT2-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LY2409021 placebo + 4 hour standardised liquid mixed-meal test + empagliflozin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2: GRA-active + MEAL + SGLT2-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + empagliflozin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B3: GRA-placebo + MEAL + SGLT2-active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B4: GRA-active + MEAL + SGLT2-active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2403021</intervention_name>
    <description>Glucagon receptor antagonist</description>
    <arm_group_label>A2: GRA-active + MEAL + DPP4-placebo</arm_group_label>
    <arm_group_label>A4: GRA-active + MEAL + DPP4-active</arm_group_label>
    <arm_group_label>B2: GRA-active + MEAL + SGLT2-placebo</arm_group_label>
    <arm_group_label>B4: GRA-active + MEAL + SGLT2-active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2403021 placebo</intervention_name>
    <arm_group_label>A1: GRA-placebo + MEAL + DPP4-placebo</arm_group_label>
    <arm_group_label>A3: GRA-placebo + MEAL + DPP4-active</arm_group_label>
    <arm_group_label>B1: GRA-placebo + MEAL + SGLT2-placebo</arm_group_label>
    <arm_group_label>B3: GRA-placebo + MEAL + SGLT2-active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standardised liquid meal</intervention_name>
    <arm_group_label>A1: GRA-placebo + MEAL + DPP4-placebo</arm_group_label>
    <arm_group_label>A2: GRA-active + MEAL + DPP4-placebo</arm_group_label>
    <arm_group_label>A3: GRA-placebo + MEAL + DPP4-active</arm_group_label>
    <arm_group_label>A4: GRA-active + MEAL + DPP4-active</arm_group_label>
    <arm_group_label>B1: GRA-placebo + MEAL + SGLT2-placebo</arm_group_label>
    <arm_group_label>B2: GRA-active + MEAL + SGLT2-placebo</arm_group_label>
    <arm_group_label>B3: GRA-placebo + MEAL + SGLT2-active</arm_group_label>
    <arm_group_label>B4: GRA-active + MEAL + SGLT2-active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>DPP-4-inhibitor</description>
    <arm_group_label>A3: GRA-placebo + MEAL + DPP4-active</arm_group_label>
    <arm_group_label>A4: GRA-active + MEAL + DPP4-active</arm_group_label>
    <other_name>Trajenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin placebo</intervention_name>
    <arm_group_label>A1: GRA-placebo + MEAL + DPP4-placebo</arm_group_label>
    <arm_group_label>A2: GRA-active + MEAL + DPP4-placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>SGLT2-inhibitor</description>
    <arm_group_label>B3: GRA-placebo + MEAL + SGLT2-active</arm_group_label>
    <arm_group_label>B4: GRA-active + MEAL + SGLT2-active</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin placebo</intervention_name>
    <arm_group_label>B1: GRA-placebo + MEAL + SGLT2-placebo</arm_group_label>
    <arm_group_label>B2: GRA-active + MEAL + SGLT2-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians above 30 years of age with diet or metformin treated type 2 diabetes for at
             least 3 months (diagnosed according to the criteria of the World Health Organization)

          -  Normal haemoglobin

          -  Informed consent

        Exclusion Criteria:

          -  Inflammatory bowel disease

          -  Intestinal resections

          -  Nephropathy (serum creatinine above normal range and/or albuminuria)

          -  Liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate
             aminotransferase (ASAT) &gt;2×normal values)

          -  Treatment with medicine that cannot be paused for 12 hours

          -  Pregnancy and/or breastfeeding

          -  Family history of pancreatic islet tumours

          -  Age above 75 years

          -  Treatment with loop-diuretics (applies only to arms with empagliflozin or
             empagliflozin placebo)

          -  Chronic heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Diabetes Research, Gentofte Hospital, Copenhagen University</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Sofie Hædersdal</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

